Literature DB >> 2154438

Pharmacokinetics of azithromycin in rats and dogs.

R M Shepard1, F C Falkner.   

Abstract

After intravenous or oral administration to rats and dogs, azithromycin was rapidly distributed into the tissues, where concentrations frequently exceeded those in serum by 100-fold or more within 24 h of a single dose. Tissue concentrations were proportional to the dose following single administrations of 10 to 40 mg/kg in rats and dogs. Tissue concentrations were higher after multiple dosing and became greater as the dose was increased from 10 to 40 mg/kg. Elimination half-lives were similar in most tissues and were about 40 h in rats after seven doses of 20 mg/kg and about 90 h in dogs after five doses of 30 mg/kg. Serum concentrations declined in a multi-exponential manner, reflecting initial rapid distribution into tissues and then slow return to serum from tissues. Azithromycin had good oral bioavailability in rats and dogs (46% and 97%, respectively). Rapid uptake of azithromycin by tissues from serum and slow redistribution from tissues to serum are apparently factors governing the pharmacokinetics of azithromycin in rats and dogs. Serum concentrations do not reflect the availability of azithromycin in tissues.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154438     DOI: 10.1093/jac/25.suppl_a.49

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  40 in total

1.  Rationale for a Neisseria gonorrhoeae Susceptible-only Interpretive Breakpoint for Azithromycin.

Authors:  Ellen N Kersh; Vanessa Allen; Eric Ransom; Matthew Schmerer; Sancta Cyr; Kim Workowski; Hillard Weinstock; Jean Patel; Mary Jane Ferraro
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

2.  Efficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model.

Authors:  E Azoulay-Dupuis; J Mohler; J P Bédos; C Barau; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects.

Authors:  G W Amsden; A N Nafziger; G Foulds
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Concentration of azithromycin in human prostatic tissue.

Authors:  G Foulds; P Madsen; C Cox; R Shepard; R Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

5.  Stimulation with cytokines enhances penetration of azithromycin into human macrophages.

Authors:  L E Bermudez; C Inderlied; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

Review 6.  The pharmacokinetics of azithromycin and their clinical significance.

Authors:  H Lode
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

7.  Concentrations of azithromycin in human tonsillar tissue.

Authors:  G Foulds; K H Chan; J T Johnson; R M Shepard; R B Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

8.  Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia.

Authors:  S Schönwald; V Skerk; I Petricevic; V Car; L Majerus-Misic; M Gunjaca
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

9.  Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.

Authors:  Mark G Papich; Marilyn N Martinez
Journal:  AAPS J       Date:  2015-04-29       Impact factor: 4.009

10.  In vitro activity of azithromycin against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.